TITLE

SENORX GETS 510(K) CLEARANCE FOR SINGLE STEP BIOPSY DEVICE

PUB. DATE
October 2002
SOURCE
Biotech Equipment Update;Oct2002, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that medical device company SenoRx Inc. has received 510 (k) clearance from U.S. Food and Drug Administration to market its Single Step breast biopsy device for the diagnosis of breast cancer. Uses of the device; Investors in the company; Other devices for which the company has received 510 (k) clearance.
ACCESSION #
9397823

 

Related Articles

  • Cancer Fighter. Gawel, Richard; Konish, Nancy // Electronic Design;06/14/99, Vol. 47 Issue 12, p64B 

    Introduces T-Scan 2000 device used in tumor detection on women breast developed by TransScan Medical Inc. in Ramsey, New Jersey. Description of the T-Scan 200 device; Efficacy and limitations of the device; Condition for the approval of the device; Contact information.

  • EXACT SCIENCES REPORTS NET LOSS OF 7.6 MILLION FOR FIRST QTR.  // Biotech Financial Reports;Jun2002, p6 

    Reports on financial results of cancer diagnostic equipment company Exact Sciences Corp. for the first quarter of 2002. Net loss reported by the company for the quarter; Factors which resulted in losses for the company; Recognition given to scientists and clinicians of the company by various...

  • Cancer Catchers. Deans, Alan // Bulletin with Newsweek;10/16/2001, Vol. 119 Issue 6297, p12 

    Details the development of Truscan, a cancer detection device. Conduction of independent trials in six countries to win approval from European regulators; Description of Truscan; Number of individual tests for the accuracy of Truscan. INSET: Healthy profits, by Alan Deans..

  • Testing of BCC detection device begins in Canada. Guttman, Cheryl // Dermatology Times;Feb2000, Vol. 21 Issue 2, p8 

    Evaluates the SCD-1 Skin Cancer Detection System from Biomax Technologies Inc. in Canada. Use of the device in delineating and defining basal cell carcinoma borders; Differentiation between normal skin and basal cell carcinoma; Analysis of tumor borders with natural room light; Removal of...

  • DELM identifies structural changes in lesions. Guttman, Cheryl // Dermatology Times;Aug2000, Vol. 21 Issue 8, p14 

    Reports on the use of digital epiluminescence microscopy in evaluating melanocytic skin lesions in patients with multiple atypical nevi. Morphologic modifications of melanomas; Characteristics of melanomas; Differentiation of melanomas from benign melanocytic lesions.

  • Early Oral Cancer Check. Bright, Jennifer // Prevention;Oct2001, Vol. 53 Issue 10, p164 

    Reports on a cancer check called OralCDx that allows dentists to take a quick, painless sample of suspicious mouth lesions which is then analyzed by computer.

  • Bloomberg.  // Business News New Jersey;4/17/96, Vol. 9 Issue 8, p56 

    Reports that Immunomedics's CEA-Scan, a cancer diagnostic product, has moved closer to the United States market after meeting agency requirements of the Food and Drug Administration.

  • SenoRx Expected to Supplement Funding Tally With $6M Round. Reed, Vita // Orange County Business Journal;3/24/2003, Vol. 26 Issue 12, p8 

    Reports that SenoRx Inc., a developer of devices to find and treat breast cancer, has set an estimated amount it will get for its funding round in 2003. List of companies that are expected to invest; SenoRx's product offering; Amount of money the company raised in 2001.

  • SenoRx Buy Sets Benchmark for Device Maker Acquisitions. REED, VITA // Orange County Business Journal;5/17/2010, Vol. 33 Issue 20, p5 

    The article reports that the 213 million dollar pending buy of SenoRx Inc. could set the tone for acquisitions.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics